* Note: Prices are in Million (M) USD.
Description:
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $136 M
Debt : $43 M
EBITDA : $23 M
Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Drug Manufacturers - Specialty & Generic
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-4 M
Average Revenue: $248 M
Revenue Converted To Free Cash FLow(%): -1%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 77.04%
Since Free Cash Flow (FCF) to Revenue percentage is negative, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $482 M
Revenue 4 Years Ago (2020-12-31): $338 M
Last 5 Years Average Revenue Growth: 8%
Since Revenue Growth is between 5 - 10, 2 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $132 M
Share Count 5 Years Ago (2020-12-31): $111 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Message: Cannot calculate payout ratio because EPS is either 0 or negative.
Using default values for calculation.
Based on default values, 1 points assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -17%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $5
52-Week Low: $2
Threshold Price (15% Above 52-Week Low): $3
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $591 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 1% exposure of Total Portfolio.
Value-Trade has assigned 14 points to above Organogenesis Holdings Inc (ORGO) stock.
Last 6 Years Avg PE (Limited to last 6 years of EPS data) 24, Fair Value PE 12, Industry Based PE is 15 and Growth based PE is 10. Based on these all values average assigned is 15.25.
The fair value of Organogenesis Holdings Inc (ORGO) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
